Novel, selective parp protein degraders for prostate cancer utilizing psma uptake enhancement
Active Project Grant Awarded Last action
- Award ID
- HT94252510160
- Recipient
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $220,326
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 79% complete
- Place of performance
- Birmingham, AL 35294, USA
Award details come from USAspending.gov.
About this award
The University of Alabama at Birmingham (UAB) was awarded a $220,326 project grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to develop novel, selective PARP protein degraders for prostate cancer treatment utilizing PSMA uptake enhancement. The award period runs from April 1, 2025 to March 31, 2027. This grant supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public by funding innovative medical solutions that address critical health challenges. UAB's research project focuses on developing novel cancer therapies that leverage PSMA, a prostate-specific membrane antigen, to selectively target and degrade PARP proteins in prostate cancer cells.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Miami | $30,000 |
Quick answers
Who received award HT94252510160?
HT94252510160 was awarded to University Of Alabama At Birmingham by Defense Health Agency (Department of Defense) on April 1, 2025.
How much is award HT94252510160 worth?
$220,326 has been obligated on HT94252510160.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award